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Abstract
There is mounting evidence, including the recent report by
Maggiore and colleagues, of an association between hyper-
natremia and mortality in patients with traumatic brain injury. This
mandates a re-evaluation of routine administration of agents such
as hypertonic saline for the management of intracranial hyper-
tension in those with traumatic brain injury.
In the previous issue of Critical Care, Maggiore and
colleagues [1] contributed significantly to our understanding
of the incidence and associated consequences of hyper-
natremia in neurocritical care. This retrospective cohort study
was performed in 130 consecutive patients with severe
traumatic brain injury admitted to a tertiary academic referral
institution. Hypernatremia was common, occurring in 51.5%
of patients for 31% of the duration of their intensive care unit
(ICU) stay. Hypernatremia was associated with a threefold
increase in hazard of ICU death, even after adjustment for
baseline risk. These results are consistent with the previous
work of Aiyagari and colleagues [2], who found that
hypernatremia was independently associated with increased
mortality but only when severe (serum sodium >160 mEq/L)
in a mixed neurocritical care sample that included patients
with traumatic brain injury.
It is important to note that these non-interventional studies
employed rigorous analytic techniques to account for the
etiology of sodium disturbance. Such complex analytic tech-
niques are required as sodium concentration abnormalities
may be due to consequences of the injury (for example,
central diabetes insipidus or hyperglycemia induced osmotic
diruesis) or may be related to treatment (for example, hyper-
tonic saline or mannitol). Maggiore and colleagues [1]
admirably performed a detailed analysis that included many
relevant potential confounders in an attempt to describe the
independent association of hypernatremia and mortality.
Arguably, potentially important covariates have been exclu-
ded. Although adjusted for baseline risk using the impact
prognostic model, the analysis did not include relevant ICU
prognostic factors such as the development and degree of
intracranial hypertension or systemic hypotension. This is
significant when considering the indications for hypertonic
saline and mannitol in neurotrauma. Both therapies are used
as treatment of intracranial hypertension, but mannitol may
potentiate systemic hypotension via osmotic diuresis.
Hypertonic saline may have also been used in response to
hyponatremia. Admittedly, one can never be certain that all
relevant covariates are included in the correct manner in such
models, and each additional covariate increases the com-
plexity of the analysis and decreases power. Thus, it remains
possible that hypernatremia is merely a marker of severity of
illness.
In the meantime, where does this leave the clinician caring for
the brain-injured patient? Should the results of Maggiore and
colleagues be disregarded? Should therapies associated
with hypernatremia, such as hypertonic saline or mannitol, be
abandoned? Clearly, a mortality signal is not something
clinicians can ignore, especially when studies are consistent.
However, the treatment of intracranial hypertension is a
generally adopted standard of care in neurotrauma. Multiple
studies have shown hypertonic saline and mannitol to be
physiologically beneficial with respect to the treatment of
intracranial hypertension [3-5]. Indeed, sudden decreases in
sodium concentrations may be detrimental in those with
reduced intracranial compliance, and the maintenance of
hypernatremia may be required [6]. There are limited human
efficacy data for hypertonic saline use in neurocritical care. In
a retrospective study, Qureshi and colleagues [7] found that
hypertonic saline infusions were associated with higher in-
hospital mortality (odds ratio 3.1, 95% confidence interval 1.1
to 10.2) after adjusting for differences between groups.
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However, the small sample size and non-randomized method-
ology limit the generalizability of these results. Importantly,
alternatives to hypertonic saline for the treatment of intra-
cranial hypertension such as mannitol may also be detri-
mental [8]. Although these limited data are insufficient to
mandate changes to standards of care, they provide ethical
justification for the examination of these standards in
randomized controlled trials.
Ultimately, the results of the study by Maggiore and
colleagues emphasize the need for prospective randomized
controlled studies in the neurotrauma population. It is clear
that our interventions have potential both for benefit and for
harm. The academic critical care community now has a
mandate to move beyond retrospective associative evidence
and examine interventions associated with sodium concen-
tration variability. A thorough examination of hypertonic saline
and mannitol for the management of intracranial hypertension
is a logical starting point given the frequency of this
indication.
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